
usd feb pm et
summari compani primarili manufactur product orthoped musculoskelet care
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
look sale rise
follow rise
plagu on-going
self-inflict suppli chain constraint
price pressur market expect
year compani set
sustain revenu growth
beyond
key compon return growth
rosa robot surgeri system
obtain fda approv rosa knee
system late januari anticip
fda approv rosa spine system
expect provid
detail progress rosa knee
launch annual aao american academi
orthoped surgeon meet
continu remedi manufactur
issu warsaw north campu facil
expect compani report oper
margin
report oper margin
low rang prior suppli chain issu
began late warsaw
think zbh share trade
ep estim peer
near fair valu suppli chain issu
disrupt plagu warsaw
indiana facil led market share
loss origin expect warsaw
plant issu resolv end
howev zbh manag expect
readi fda reinspect
although orthoped surgeri tend
sticki custom extend period
zbh manufactur undercapac may
led signific market share loss howev
think new product launch includ
robot applic knee could help
drive sale growth also think long-term
global demand driver orthoped
popul rise obes level
risk recommend target
includ weak perform upcom
recent product launch delay
remedi zbh manufactur
target price
below-p multipl
ep estim
recov suppli chain constraint
risk assess reflect zimmer oper
highli competit industri character rel
short product life cycl requir signific number
new product maintain market share mani custom
reimburs medicar restrict
budgetari environ could result price pressur
howev think market leadership posit
divers product offer allevi inher
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview zimmer biomet global leader musculoskelet healthcar form
june merger zimmer hold biomet primarili design develop
manufactur market orthopaed reconstruct product sport medicin biolog extrem
trauma product offic base technolog spine craniomaxillofaci thorac product dental
implant relat surgic product market sell product three princip
channel direct healthcar institut hospit stock distributor
healthcar dealer directli dental practic dental laboratori break offer
product categori knee revenu hip dental spine
 cmf
reconstruct implant use restor function lost due diseas trauma joint
knee hip shoulder elbow knee product total knee replac surgeri joint
replac partial knee reconstruct earli intervent joint preserv hip offer
product total hip replac hip implant procedur involv use bone cement attach
affix prosthet compon surround bone product categori
includ surgic sport medicin biolog foot ankl extrem trauma product
zbh spine product busi manufactur devic surgic instrument deliv comprehens
solut individu back neck pain caus degen condit deform
traumat injuri spine cmf divis includ face skull reconstruct product addit
product fixat stabil bone chest dental product primarili compris dental
reconstruct implant dental prosthet product dental regen product
competit landscap orthopaed broader musculoskelet care industri highli
competit global market zbh knee hip product major competitor includ
depuy synth compani johnson johnson stryker corpor smith nephew plc
spine cmf categori compet global primarili spinal biolog busi
plc depuy synth compani stryker corpor inc globu medic inc
dental implant categori compet primarili nobel biocar hold ag part
corpor straumann hold ag
competit within industri primarili base price technolog innov qualiti reput
custom servic key factor zbh continu success futur abil develop
new product improv exist product technolog
impact major develop receiv mani food drug
administr fda detail observ need correct zbh warsaw indiana-bas plant
continu remedi manufactur issu manufactur remedi
process result inventori constraint caus cut guidanc multipl time
expect zbh inventori issu resolv late
june zimmer acquir biomet billion connect transact zimmer
chang name zimmer biomet ticker symbol new york stock exchang
zmh combin compani leader musculoskelet market juli zimmer acquir
ldr hold billion ldr medic devic compani focus proprietari surgic
technolog treatment patient suffer spinal disord
financi trend revenu dec increas billion billion adjust
ep grew slightli growth pressur zbh remedi
effort manufactur plant warsaw indiana march zbh net debt total capit
leverag ratio net debt ebitda zbh free cash flow defin cash flow
oper less capit expenditur declin slightli billion
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
bullish sinc februari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral slightli posit continu
expect compani sub-industri
grow posit macro environ
compani gener benefit
laxer food drug administr fda
technolog advanc sub-industri
also mani product area
equip use non-elect procedur
howev valuat high industri
investor sentiment medic devic
compani appear shaken
volatil late think
higher valuat sub-industri
mostli warrant recent expand
margin robust revenu growth weaker
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess headwind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
although chines
govern seek lower health care cost
equip manufactur insul
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
take control hous
repres think see
significantli lower level effort
republican trump administr
tri repeal
hospit spend larg driver medic
equip sale robust
strong economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index rose vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
below-p ep estim set ep
ep vs line view sale rose knee
hip believ new ceo hanson face challeng
tackl qualiti issu warsaw plant suppli chain constraint
result market share loss believ longer issu continu
difficult regain market share think new product launch includ robot
applic knee help drive sale /jeffrey loo cfa
hold inc lower target price
below-p forward ep estim see
continu suppli chain challeng advers impact sale market share
think capac issu warsaw plant continu
could put share risk ep vs
estim lower ep estim
sale fell knee product hip
 sale rose knee sale hurt lower price
analyst research note compani news
pm et cfra maintain hold opinion share zimmer biomet
hold inc lower target
ep estim -- peer-averag due continu
remedi effort need address fda concern ep vs
consensu lower ep estim
start sale rose yoy constant currenc
billion constant currenc basi revenu yoy
america grew emea asia pacif respect
 spine fastest grow product categori quarter
experienc constant currenc sale increas full year
grew cash oper activ impress versu
declin aid solid progress made suppli recoveri
reduct back order expect year compani
set sustain revenu growth beyond /colin
hold inc maintain target
below-p ep estim lower multipl
reflect continu remedi effort address fda concern initi
highlight novemb ep vs lower
estim maintain ep lower ep
sale increas constant currenc billion
strengthen dollar stronger neg expect quarter
expect even stronger headwind vs
constant currenc basi revenu grew america flat emea
grew asia pacif reassur investor two largest
upcom project persona revis system new rosa robot
applic progress well await regulatori approv
expect year compani set sustain
revenu growth beyond /kevin huang cfa
hold inc lift target
below-p ep estim lower
multipl reflect zbh on-going effort remedi violat key
plant highlight fda initi novemb ep vs
higher estim lower ep
ep sale increas
constant currenc billion constant currenc basi
revenu grew america declin emea grew
asia pacif cautious optimist zbh suppli recoveri
remedi effort compani think achiev
above-market growth rate though expect constant
hold inc keep target
below-p ep estim reflect
on-going effort remedi violat key plant highlight fda
initi novemb ep vs higher
estim lower ep ep estim
sale increas billion
constant currenc basi decreas except
product categori grew product line experienc
constant-curr revenu declin low-singl digit encourag
ceo effort make chang leadership build better cultur
could reduc risk face futur complianc issu
hand fda addit observ late-april
inspect ceo comment go two-year
hold inc keep target
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
